Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.42 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372437 | 0.93 | JAK2 (0.47) | JAK2TYK2GSK3B | |
| SCHEMBL2372204 | 0.87 | JAK2 (0.56) | PTGESJAK2TYK2GSK3BCYP2C9 | |
| SCHEMBL2372752 | 0.85 | CHEK1 (0.44) | PTGESJAK2TYK2GSK3B | |
| SCHEMBL2371762 | 0.85 | PTGES (0.42) | PTGESJAK2TYK2GSK3BGCK | |
| SCHEMBL2371819 | 0.84 | JAK2 (0.43) | PTGESJAK2TYK2 | |
| SCHEMBL2371849 | 0.82 | PTGES (0.46) | PTGESJAK2TYK2GSK3B | |
| SCHEMBL2370265 | 0.82 | PTGES (0.43) | PTGESJAK2TYK2GSK3B | |
| SCHEMBL2372347 | 0.82 | JAK2 (0.54) | PTGESJAK2TYK2GSK3B | |
| SCHEMBL2371755 | 0.81 | PTGES (0.42) | PTGESJAK2TYK2GSK3B | |
| SCHEMBL2372329 | 0.80 | JAK2 (0.58) | PTGESJAK2TYK2GSK3BCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2547338-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096104-A1 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TYK2, IRAK1, IRAK4 | PTGES 1438/4885JAK2 6/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.